Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fovista + Lucentis in wet AMD (OPH1002)
NCT01944839Phase 3Terminated
- Sponsor
- IVERIC bio
- Start
- Aug 2013
- Primary completion
- Dec 2016
- Modality
- Polymer-based Nanoparticles, RNA Aptamers, DNA Aptamers
- Countries
- 13
01
Overview
A Phase 3 trial of pegpleranib in exudative macular degeneration, sponsored by IVERIC bio. Started Aug 2013; status: terminated.
02
Drugs
pegpleranib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT01944839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01944839.